ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JBI-802

Its studies are mostly in Thrombocythemia, Essential · Neoplasm Metastasis, led by Jubilant Therapeutics.

Drug pageJBI-802: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 11, 20222 company-led studies, 2 open or runningNext primary completion: Jan 30, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jubilant Therapeutics22 open or runningphase 2since Feb 11, 2022Feb 11, 2022Jan 30, 2031phase 2 · NCT07612280

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2022First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05268666 · 126 planned · United States
  2. Aug 11, 2025Phase 2 study in Thrombocythemia, EssentialNCT07612280 · 70 planned · Australia

Ahead

  1. Jan 30, 2031Primary completion: phase 2 study in Thrombocythemia, EssentialNCT07612280

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07612280Thrombocythemia, Essential · Australia2RecruitingJan 30, 203170
NCT05268666Neoplasm Metastasis · United States2RecruitingDec 2024126

How it is read

Names in the registry

  • “JBI-802”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.